GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » Equity-to-Asset

Synthorx (Synthorx) Equity-to-Asset : 0.93 (As of Sep. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Synthorx Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Synthorx's Total Stockholders Equity for the quarter that ended in Sep. 2019 was $151.96 Mil. Synthorx's Total Assets for the quarter that ended in Sep. 2019 was $163.67 Mil.

The historical rank and industry rank for Synthorx's Equity-to-Asset or its related term are showing as below:

THOR's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

Synthorx Equity-to-Asset Historical Data

The historical data trend for Synthorx's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthorx Equity-to-Asset Chart

Synthorx Annual Data
Trend Dec16 Dec17 Dec18
Equity-to-Asset
-1.48 -2.80 0.96

Synthorx Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only 0.91 0.96 0.94 0.94 0.93

Competitive Comparison of Synthorx's Equity-to-Asset

For the Biotechnology subindustry, Synthorx's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synthorx's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthorx's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Synthorx's Equity-to-Asset falls into.



Synthorx Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Synthorx's Equity to Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Equity to Asset (A: Dec. 2018 )=Total Stockholders Equity/Total Assets
=184.36/191.506
=

Synthorx's Equity to Asset Ratio for the quarter that ended in Sep. 2019 is calculated as

Equity to Asset (Q: Sep. 2019 )=Total Stockholders Equity/Total Assets
=151.963/163.671
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synthorx  (NAS:THOR) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Synthorx Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Synthorx's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Synthorx (Synthorx) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037
Executives
Powell Andrew Kenneth William director C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver director, officer: President and CEO 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p. 10 percent owner 1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022